FDA recall record

AJC International Early Dawn recall — FDA F-0563-2018

Early Dawn Whole Tilapia was sampled and found positive for the antibiotic, Sulfadiazine.

Class IIclassification
F-0563-2018official record ID
Jan 10, 2018report date

Recall record at a glance

Official recordF-0563-2018
CategoryFood Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmAJC International, Inc.
Report dateJan 10, 2018
Recall initiation dateDec 22, 2017
Quantity169 cases
LocationAtlanta, GA, United States

Official product description

Early Dawn; Whole Tilapia IQF, Gutted & Scaled, Farm Raised, 40 lbs.; Size 550-750g OR 750g+, Lot No.: 1985507; Production Date: 08/12/2017; Best Used By Date: 02/12/2019; Product of China.

Why the product was recalled

Early Dawn Whole Tilapia was sampled and found positive for the antibiotic, Sulfadiazine.

Distribution information

PA

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: E-Mail.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.